Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery

Y. D. Kim, M. L. Foegh, R. B. Wallace, L. Ng, S. W. Ahmed, N. M. Katz, R. Siegelman, K. Franco, F. Douglas, E. Ku, B. Sen, P. Ramwell

Research output: Contribution to journalArticle

Abstract

Pulmonary hypertension with an elevated pulmonary vascular resistance was observed during the immediate recovery period in patients who underwent mitral valve surgery. In eight such patients, intravenous infusion of CGS-13080, imidazo(1,5-a)pyridine-5-hexanoic acid (a thromboxane synthetase inhibitor), at a dose range of 0.08-0.1 mg/kg/hr, effectively reduced pulmonary hypertension (from a mean pulmonary arterial pressure of 36 ± 2 to 31 ± 2 torr) and pulmonary vascular resistance (from 339 ± 38 to 238 ± 37 dynes · sec · cm-5) within 30 minutes and remained reduced for the entire infusion period (48 hours in five patients and 18 hours in three patients). Mean arterial pressure or systemic vascular resistance were not significantly affected by the drug infusion. Serum thromboxane B2 levels (a stable metabolic product of thromboxane A2) were significantly reduced after administration of the compound, with the maximum effect of greater than 90% reduction. All patients tolerated the drug infusion without significant side effects.

Original languageEnglish (US)
JournalCirculation
Volume78
Issue number3 II SUPPL.
StatePublished - 1988
Externally publishedYes

Fingerprint

Thromboxanes
Mitral Valve
Vascular Resistance
Pulmonary Hypertension
Arterial Pressure
Thromboxane-A Synthase
Thromboxane B2
Thromboxane A2
Intravenous Infusions
Pharmaceutical Preparations
pirmagrel
Lung
Serum

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Kim, Y. D., Foegh, M. L., Wallace, R. B., Ng, L., Ahmed, S. W., Katz, N. M., ... Ramwell, P. (1988). Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery. Circulation, 78(3 II SUPPL.).

Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery. / Kim, Y. D.; Foegh, M. L.; Wallace, R. B.; Ng, L.; Ahmed, S. W.; Katz, N. M.; Siegelman, R.; Franco, K.; Douglas, F.; Ku, E.; Sen, B.; Ramwell, P.

In: Circulation, Vol. 78, No. 3 II SUPPL., 1988.

Research output: Contribution to journalArticle

Kim, YD, Foegh, ML, Wallace, RB, Ng, L, Ahmed, SW, Katz, NM, Siegelman, R, Franco, K, Douglas, F, Ku, E, Sen, B & Ramwell, P 1988, 'Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery', Circulation, vol. 78, no. 3 II SUPPL..
Kim, Y. D. ; Foegh, M. L. ; Wallace, R. B. ; Ng, L. ; Ahmed, S. W. ; Katz, N. M. ; Siegelman, R. ; Franco, K. ; Douglas, F. ; Ku, E. ; Sen, B. ; Ramwell, P. / Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery. In: Circulation. 1988 ; Vol. 78, No. 3 II SUPPL.
@article{b8c7bd7d0d93436a872151cd998b06f4,
title = "Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery",
abstract = "Pulmonary hypertension with an elevated pulmonary vascular resistance was observed during the immediate recovery period in patients who underwent mitral valve surgery. In eight such patients, intravenous infusion of CGS-13080, imidazo(1,5-a)pyridine-5-hexanoic acid (a thromboxane synthetase inhibitor), at a dose range of 0.08-0.1 mg/kg/hr, effectively reduced pulmonary hypertension (from a mean pulmonary arterial pressure of 36 ± 2 to 31 ± 2 torr) and pulmonary vascular resistance (from 339 ± 38 to 238 ± 37 dynes · sec · cm-5) within 30 minutes and remained reduced for the entire infusion period (48 hours in five patients and 18 hours in three patients). Mean arterial pressure or systemic vascular resistance were not significantly affected by the drug infusion. Serum thromboxane B2 levels (a stable metabolic product of thromboxane A2) were significantly reduced after administration of the compound, with the maximum effect of greater than 90{\%} reduction. All patients tolerated the drug infusion without significant side effects.",
author = "Kim, {Y. D.} and Foegh, {M. L.} and Wallace, {R. B.} and L. Ng and Ahmed, {S. W.} and Katz, {N. M.} and R. Siegelman and K. Franco and F. Douglas and E. Ku and B. Sen and P. Ramwell",
year = "1988",
language = "English (US)",
volume = "78",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "3 II SUPPL.",

}

TY - JOUR

T1 - Effects of CGS-13080, a thromboxane inhibitor, on pulmonary vascular resistance in patients after mitral valve replacement surgery

AU - Kim, Y. D.

AU - Foegh, M. L.

AU - Wallace, R. B.

AU - Ng, L.

AU - Ahmed, S. W.

AU - Katz, N. M.

AU - Siegelman, R.

AU - Franco, K.

AU - Douglas, F.

AU - Ku, E.

AU - Sen, B.

AU - Ramwell, P.

PY - 1988

Y1 - 1988

N2 - Pulmonary hypertension with an elevated pulmonary vascular resistance was observed during the immediate recovery period in patients who underwent mitral valve surgery. In eight such patients, intravenous infusion of CGS-13080, imidazo(1,5-a)pyridine-5-hexanoic acid (a thromboxane synthetase inhibitor), at a dose range of 0.08-0.1 mg/kg/hr, effectively reduced pulmonary hypertension (from a mean pulmonary arterial pressure of 36 ± 2 to 31 ± 2 torr) and pulmonary vascular resistance (from 339 ± 38 to 238 ± 37 dynes · sec · cm-5) within 30 minutes and remained reduced for the entire infusion period (48 hours in five patients and 18 hours in three patients). Mean arterial pressure or systemic vascular resistance were not significantly affected by the drug infusion. Serum thromboxane B2 levels (a stable metabolic product of thromboxane A2) were significantly reduced after administration of the compound, with the maximum effect of greater than 90% reduction. All patients tolerated the drug infusion without significant side effects.

AB - Pulmonary hypertension with an elevated pulmonary vascular resistance was observed during the immediate recovery period in patients who underwent mitral valve surgery. In eight such patients, intravenous infusion of CGS-13080, imidazo(1,5-a)pyridine-5-hexanoic acid (a thromboxane synthetase inhibitor), at a dose range of 0.08-0.1 mg/kg/hr, effectively reduced pulmonary hypertension (from a mean pulmonary arterial pressure of 36 ± 2 to 31 ± 2 torr) and pulmonary vascular resistance (from 339 ± 38 to 238 ± 37 dynes · sec · cm-5) within 30 minutes and remained reduced for the entire infusion period (48 hours in five patients and 18 hours in three patients). Mean arterial pressure or systemic vascular resistance were not significantly affected by the drug infusion. Serum thromboxane B2 levels (a stable metabolic product of thromboxane A2) were significantly reduced after administration of the compound, with the maximum effect of greater than 90% reduction. All patients tolerated the drug infusion without significant side effects.

UR - http://www.scopus.com/inward/record.url?scp=0023690727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023690727&partnerID=8YFLogxK

M3 - Article

C2 - 3409518

AN - SCOPUS:0023690727

VL - 78

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 3 II SUPPL.

ER -